Therapy	Strength or type of recommendation	Recommendation
Casirivimab plus imdevimab	Conditional recommendation	Consider using casirivimab plus imdevimab within 7 days of symptom onset in pregnant or breastfeeding women with COVID‐19 who do not require supplemental oxygen and have one or more risk factors for disease progression.
Corticosteroids (inhaled)	Conditional recommendation	Consider using inhaled corticosteroids (budesonide or ciclesonide) within 14 days of symptom onset in adults with COVID‐19 who do not require supplemental oxygen and who have one or more risk factors for disease progression. Budesonide and ciclesonide are safe to use in pregnant and breastfeeding women.
Corticosteroids (systemic)	Recommended	Use dexamethasone 6 mg intravenously or orally for up to 10 days in pregnant or breastfeeding women with COVID‐19 who require supplemental oxygen (including mechanically ventilated patients).
Molnupiravir	Only in research settings	Do not use molnupiravir for the treatment of COVID‐19 in pregnant or breastfeeding women outside of randomised clinical trials with appropriate ethics approval.
Nirmatrelvir plus ritonavir	Only in research settings	Do not use nirmatrelvir plus ritonavir for the treatment of COVID‐19 in pregnant or breastfeeding women outside of randomised clinical trials with appropriate ethics approval.
Baricitinib	Only in research settings	Do not use baricitinib for the treatment of COVID‐19 in pregnant or breastfeeding women outside randomised clinical trials with appropriate ethics approval.
Sarilumab	Only in research settings	Do not use sarilumab for the treatment of COVID‐19 in pregnant or breastfeeding women outside randomised clinical trials with appropriate ethics approval.
Tocilizumab	Conditional recommendation	Consider using tocilizumab (see the National COVID‐19 Clinical Evidence Taskforce website for doses) for the treatment of COVID‐19 in pregnant or breastfeeding women who require supplemental oxygen, particularly where there is evidence of systemic inflammation.
Remdesivir	Conditional recommendation	Consider using remdesivir in pregnant or breastfeeding women hospitalised with COVID‐19 who require supplemental oxygen but do not require non‐invasive or invasive ventilation.
Sotrovimab	Conditional recommendation	Consider using sotrovimab within 5 days of symptom onset in pregnant women with COVID‐19 in the second or third trimester who do not require oxygen and who have one or more additional risk factors for disease progression (see the National COVID‐19 Clinical Evidence Taskforce website for risk factors).
Tixagevimab plus cilgavimab	Only in research settings	Do not use tixagevimab plus cilgavimab for the treatment of COVID‐19 in pregnant or breastfeeding women outside of randomised clinical trials with appropriate ethics approval.
VTE prophylaxis	Consensus recommendation	For pregnant or post‐partum women who are admitted to hospital (for any indication) and who have COVID‐19, use prophylactic doses of anticoagulants, preferably LMWH (eg, enoxaparin 40 mg once daily or dalteparin 5000 IU once daily) unless there is a contraindication, such as risk of major bleeding or imminent birth.
	Consensus recommendation	For pregnant or post‐partum women who are self‐isolating at home with mild COVID‐19 and where additional risk factors for VTE are present, consider using prophylactic doses of anticoagulants, preferably LMWH (eg, enoxaparin 40 mg once daily or dalteparin 5000 IU once daily) unless there is a contraindication, such as risk of major bleeding or imminent birth. Prophylactic anticoagulants should be continued for at least 14 days or until COVID‐19‐related morbidity (including immobility, dehydration and shortness of breath) has resolved.
	Consensus recommendation	For post‐partum women who have had COVID‐19 during pregnancy, consider using at least 14 days of prophylactic dosing of anticoagulants, preferably LMWH (eg, enoxaparin 40 mg once daily or dalteparin 5000 IU once daily) unless there is a contraindication, such as risk of major bleeding. Increased duration of 6 weeks should be considered if severe or critical COVID‐19 and/or additional risk factors for VTE are present.
Other disease‐modifying treatments that are not recommended	Not recommended	Do not use aspirin, azithromycin, colchicine, convalescent plasma, hydroxychloroquine, hydroxychloroquine plus azithromycin, interferon‐β‐1a, lopinavir–ritonavir, interferon‐β‐1a plus lopinavir–ritonavir or ivermectin for the treatment of COVID‐19.

^*Up to date as of 24 April 2022 (see https://covid19evidence.net.au/#living‐guidelines for detailed recommendations). COVID‐19 = coronavirus disease 2019. LMWH = low‐molecular‐weight heparin. VTE = venous thromboembolism.